{"id":609,"date":"2026-08-19T05:07:21","date_gmt":"2026-08-19T09:07:21","guid":{"rendered":"http:\/\/pharmascience.local\/contact\/"},"modified":"2026-09-03T13:44:09","modified_gmt":"2026-09-03T17:44:09","slug":"contact","status":"publish","type":"page","link":"https:\/\/lms.clearoute.dev\/en\/contact\/","title":{"rendered":"Contact"},"content":{"rendered":"\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-ecd24f2a wp-block-group-is-layout-constrained\">\n\n<h1 class=\"wp-block-heading\">Contact<\/h1>\n\n\n\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n\n<h2 class=\"wp-block-heading\">Medical information<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For questions about the program or <sup>N<\/sup>pms-BUPRENORPHINE-NALOXONE, please contact the Medical Information team by calling toll-free at <a href=\"tel:+18885506060\">1-888-550-6060<\/a> or by email at: <a href=\"mailto:medinfo@pharmascience.com\">medinfo@pharmascience.com<\/a><\/p>\n\n<\/div>\n\n\n\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n\n<h2 class=\"wp-block-heading\">Adverse event reporting<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Healthcare professionals are encouraged to report adverse events associated with <sup>N<\/sup>pms-BUPRENORPHINE-NALOXONE through one of the following options:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n\n<li>Directly to <strong>Pharmascience<\/strong> by calling (toll-free) <a href=\"tel:+18885506060\">1-888-550-6060<\/a> or you can report online at <a href=\"https:\/\/intakepms.my.site.com\/s\/IntakeWebForm?language=en_CA&amp;m=hcp\" target=\"_blank\" rel=\"noreferrer noopener\">IntakeWebForm<\/a><\/li>\n\n\n\n<li>To <strong>Health Canada<\/strong> by calling <a href=\"tel:+18662342345\">1-866-234-2345<\/a> or by reporting online through <a href=\"https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/medeffect-canada\/adverse-reaction-reporting.html\" target=\"_blank\" rel=\"noreferrer noopener\">Adverse Reaction Reporting<\/a>.<\/li>\n\n<\/ul>\n\n<\/div>\n\n\n\n<div class=\"wp-block-group is-layout-flow wp-block-group-is-layout-flow\">\n\n<h2 class=\"wp-block-heading\">Technical support<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For technical issues with this website, please contact Clearoute Support by email at: <a href=\"mailto:techsupport@clearoute.com\">techsupport@clearoute.com<\/a><\/p>\n\n<\/div>\n\n\n\n<div class=\"wp-block-buttons bnrmp-back-home is-layout-flex wp-block-buttons-is-layout-flex\">\n\n<div class=\"wp-block-button is-style-bnrmp-outline\"><a class=\"wp-block-button__link wp-element-button\" href=\"\/\">Back to Home<\/a><\/div>\n\n<\/div>\n\n<\/div>\n\n\n\n","protected":false},"excerpt":{"rendered":"<p>Contact Medical information For questions about the program or Npms-BUPRENORPHINE-NALOXONE, please contact the Medical Information team by calling toll-free at 1-888-550-6060 or by email at: medinfo@pharmascience.com Adverse event reporting Healthcare professionals are encouraged to report adverse events associated with Npms-BUPRENORPHINE-NALOXONE through one of the following options: Technical support For technical issues with this website, please [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-609","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Contact - pharmascience<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Contact - pharmascience\" \/>\n<meta property=\"og:description\" content=\"Contact Medical information For questions about the program or Npms-BUPRENORPHINE-NALOXONE, please contact the Medical Information team by calling toll-free at 1-888-550-6060 or by email at: medinfo@pharmascience.com Adverse event reporting Healthcare professionals are encouraged to report adverse events associated with Npms-BUPRENORPHINE-NALOXONE through one of the following options: Technical support For technical issues with this website, please [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/lms.clearoute.dev\/en\/contact\/\" \/>\n<meta property=\"og:site_name\" content=\"pharmascience\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-03T17:44:09+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/contact\\\/\",\"url\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/contact\\\/\",\"name\":\"Contact - pharmascience\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/#website\"},\"datePublished\":\"2026-08-19T09:07:21+00:00\",\"dateModified\":\"2026-09-03T17:44:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/contact\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/contact\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/contact\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Contact &#038; support\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/\",\"name\":\"pharmascience\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/lms.clearoute.dev\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Contact - pharmascience","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Contact - pharmascience","og_description":"Contact Medical information For questions about the program or Npms-BUPRENORPHINE-NALOXONE, please contact the Medical Information team by calling toll-free at 1-888-550-6060 or by email at: medinfo@pharmascience.com Adverse event reporting Healthcare professionals are encouraged to report adverse events associated with Npms-BUPRENORPHINE-NALOXONE through one of the following options: Technical support For technical issues with this website, please [&hellip;]","og_url":"https:\/\/lms.clearoute.dev\/en\/contact\/","og_site_name":"pharmascience","article_modified_time":"2026-09-03T17:44:09+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/lms.clearoute.dev\/en\/contact\/","url":"https:\/\/lms.clearoute.dev\/en\/contact\/","name":"Contact - pharmascience","isPartOf":{"@id":"https:\/\/lms.clearoute.dev\/en\/#website"},"datePublished":"2026-08-19T09:07:21+00:00","dateModified":"2026-09-03T17:44:09+00:00","breadcrumb":{"@id":"https:\/\/lms.clearoute.dev\/en\/contact\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lms.clearoute.dev\/en\/contact\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lms.clearoute.dev\/en\/contact\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/lms.clearoute.dev\/en\/"},{"@type":"ListItem","position":2,"name":"Contact &#038; support"}]},{"@type":"WebSite","@id":"https:\/\/lms.clearoute.dev\/en\/#website","url":"https:\/\/lms.clearoute.dev\/en\/","name":"pharmascience","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lms.clearoute.dev\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/pages\/609","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/comments?post=609"}],"version-history":[{"count":14,"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/pages\/609\/revisions"}],"predecessor-version":[{"id":1308,"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/pages\/609\/revisions\/1308"}],"wp:attachment":[{"href":"https:\/\/lms.clearoute.dev\/en\/wp-json\/wp\/v2\/media?parent=609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}